2-4 , the broad applicability of this treatment is hampered by severe cytokine release syndrome (CRS), which is characterized by fever, hypotension and respiratory insufficiency associated with elevated serum cytokines, including interleukin-6 (IL-6) 2, 5 . CRS usually occurs within days of T cell infusion at the peak of CAR T cell expansion. In ALL, it is most frequent and more severe in patients with high tumor burden 2-4 . CRS may respond to IL-6 receptor blockade but can require further treatment with high dose corticosteroids to curb potentially lethal severity [2] [3] [4] [5] [6] [7] [8] [9] . Improved therapeutic and preventive treatments require a better understanding of CRS physiopathology, which has so far remained elusive. Here we report a murine model of CRS that develops within 2-3 d of CAR T cell infusion and that is potentially lethal and responsive to IL-6 receptor blockade. We show that its severity is mediated not by CAR T cell-derived cytokines, but by IL-6, IL-1 and nitric oxide (NO) produced by recipient macrophages, which enables new therapeutic interventions.
. The overall levels of these cytokines, including mouse IL-6 (mIL-6), mouse chemokine (C-C motif) ligand 2 (mCCL2), mouse granulocyte colonystimulating factor (mG-CSF), human interferon-γ (hIFN-γ ), hIL-3, human granulocyte-macrophage-CSF (hGM-CSF) and hIL-2, correlated strongly with CRS severity and survival (Fig. 1e) . Taking advantage of the xenogeneic nature of this model to discern the T cell or host cell origin of these cytokines and chemokines, we demonstrated that some cytokines, such as IFN-γ and GM-CSF, were products of human CAR T cells, whereas others, such as IL-6, were produced by endogenous mouse cells ( Fig. 1f and Supplementary  Fig. 1b ). This finding establishes that the CRS cytokine signature is the result of a multicellular network and not merely a binary tumor-CAR T cell interaction. Furthermore, the lack of activity of hIFN-γ and hGM-CSF on the mouse cognate receptor (Supplementary Table 2 ) indicates that other CAR T cell-derived cytokines and/ or CAR T cell activities account for CRS. Although dispensable in this model, T cell-derived IFN-γ and GM-CSF may yet contribute to CRS in other settings. Consistent with clinical CRS 11 , IL-15 was not differentially elevated upon CAR transfer ( Supplementary Fig.  1c ). In accordance with clinical experience 2, 3, 9, 10 , treating mice with a mIL-6R-blocking antibody prevented CRS-associated mortality ( Fig. 1g and Supplementary Fig. 1d ).
Histopathological analyses performed 2 and 5 d after CAR T cell infusion did not reveal any evidence of graft-versus-host disease (GVHD) or tissue destruction ( Supplementary Fig. 2 ), consistent with the initiation of this inflammatory response following tumor recognition by CAR T cells as well as the full recovery of mice surviving CRS. Histopathological examination of the central nervous system (CNS) and meninges at 1, 2 and 5 d after CAR T cell transfer did not reveal morphological evidence of acute damage or toxicity ( Supplementary Fig. 3 ), consistent with the absence of overt neurological symptoms (seizures, limb dyskinesia or paralysis). None of the reported pathologic findings indicative of neuropathology 15 or associated with neurotoxicity (cortical laminar necrosis, hemorrhages, disseminated intravascular coagulation (DIC), gliosis or vasogenic, neurotoxic or interstitial edema) in human patients 16 were observed in any of the mice examined in the present study. The occurrence of subclinical functional alterations or ultrastructural morphological changes cannot be excluded. Mice surviving CRS rapidly returned to a highly active state, akin to healthy, tumorfree mice. No clinical neurological anomalies were noted until mice were euthanized because of tumor progression.
The high serum levels of mIL-6, a predominantly myeloid-derived cytokine, together with the presence of tumor-infiltrating myeloid cells ( injected in mice and allowed to grow for 3 weeks, and they eventually grew into vascularized solid tumor masses. Thirty million CAR T cells were transferred, and mice were monitored over the days following transfer. Mice were euthanized, and cells were obtained for analysis through peritoneal lavage and tissue harvesting. b, Weight change of tumor-bearing mice after 1928z CAR T cell transfer. Weight per mouse is normalized to starting weight before CAR transfer (Tumor only, n = 12 mice; Tumor + CAR, n = 18 mice). At least 20 independent experiments monitoring weight under CRS-eliciting conditions were performed. A two-way ANOVA was used for statistical analysis. c, Percentage of survival of mice after 1928z CAR T cell transfer (Tumor only, n = 12 mice, Tumor + CAR, n = 18 mice). At least 20 independent experiments monitoring survival under CRS-eliciting conditions were performed. A log-rank Mantel-Cox test was used for statistical analysis. d, Serum levels of mSAA3 at 42 h after 1928z CAR T cell transfer as measured using ELISA (No tumor + No CAR, n = 5 mice; Tumor only, n = 5 mice; CAR only, n = 5 mice; Tumor + CAR, n = 7 mice). SAA3 levels under CRS-eliciting conditions were measured in at least in two independent experiments. A two-tailed unpaired two-sample t-test was used for statistical analysis. e, Serum cytokine levels 4.5 h before (pre-CAR) and 24 h after 1928z CAR T cell transfer. Mice that eventually died from CRS were grouped under Severe CRS, whereas mice that survived but lost more than 10% of their initial body weight were grouped under CRS (Severe CRS, n = 5 mice; CRS, n = 10 mice; pre-CAR, n = 16 mice). Stratification of cytokines on the basis of survival was performed in at least three independent experiments. A two-tailed unpaired two-sample t-test was used for statistical analysis. f, Species of origin of proinflammatory cytokines (human cytokines from n = 15 mice; mouse cytokines from n = 15 mice). g, Percentage of survival of tumor-bearing mice treated with 1928z CAR T cells that received anti-mIL-6R blocking antibody or isotype (vehicle) (Vehicle, n = 6 mice; Anti-mIL-6R, n = 5 mice). Experiments measuring survival after blocking mIL-6R were performed once. A log-rank Mantel-Cox test was used for statistical analysis. All data are shown as mean ± s.e.m. Numbers on the graphs are P values. ). Cells were obtained from peritoneal lavage. Analysis of peritoneal macrophages for levels of F4/80 and Ly6C was performed at least 10 times. d, Absolute counts of myeloid cell populations obtained from multiple organs 18 h after 1928z CAR T cell transfer (Tumor only, n = 4 mice; Tumor + CAR n = 4 mice). Enumeration of cells retrieved from peritoneum, spleen and bone marrow under CRS conditions was performed at least three times. A two-tailed unpaired two-sample t-test was used for statistical analysis. e,f, Fold change of proinflammatory cytokine gene expression in myeloid populations as determined by RNA-seq analysis. Fold change was determined by comparing each population under Tumor only and Tumor + CAR conditions. Green bars, significant downregulation; red bars, significant upregulation; gray bars, no significant change. Gene expression levels were determined from cells obtained from n = 9 Tumor only mice and n = 9 Tumor + CAR mice. Cells from three mice of the same group were randomly pooled to create one biological replicate group for the purpose of obtaining three biological replicate groups of Tumor only mice and three biological replicate groups of Tumor + CAR mice. A binomial test was used for statistical analysis, and P values were adjusted for false discovery rate (FDR). All data are shown as mean ± s.e.m. except for that in e-g, in which data are shown as mean ± s.d. Numbers on the graphs are P values. (Fig. 2c) . The rapid elevation of myeloid cell numbers, which was already noticeable 18 h after CAR T cell administration (Fig. 2d) , suggested that recruitment was a major contributor to myeloid accumulation. RNA-seq analyses at 18 h showed increased expression of genes promoting the cell cycle, suggesting that cell proliferation may play a secondary role in local myeloid cell accumulation.
To address whether these alterations were regional or systemic, we enumerated neutrophils, eosinophils, DCs, monocytes and macrophages in spleen, bone marrow, lungs, liver and peripheral blood ( Fig. 2d and Supplementary Fig. 4b ). Whereas neutrophils, DCs and macrophages accumulated at the tumor site, systemic perturbations were limited to increased counts of macrophages in spleen ( Fig. 2d ) and of neutrophils in peripheral blood, coinciding with neutrophil depletion in bone marrow ( Fig. 2d and Supplementary Fig. 4b ). The major alterations in myeloid cell distribution were thus confined to the tumor vicinity and to the spleen.
As IL-6 is a signature cytokine of CRS, we hypothesized that tracking down IL-6-producing cells would identify the main physiopathological sites. We therefore purified DC, macrophage and monocytic populations from peritoneum and spleen (IL-6 is not typically produced by neutrophils 17 ) ( Supplementary Fig. 5a ,b) and performed RNA-seq analysis. Remarkably, only peritoneal, but not splenic, DCs, monocytes and macrophages showed upregulated IL-6 transcripts ( Fig. 2e,f) . The induction of other major proinflammatory cytokines was likewise confined to the site of CAR T cell-tumor tissue colocalization (Fig. 2e,f) . Combined with cell-enumeration data, macrophages emerged as the main overall source of IL-6. As CAR T cells were found in the peritoneum, but not the spleen or other organs ( Supplementary Fig. 4c ), these findings further suggest that IL-6 induction and myeloid activation require proximity of CAR T cells and myeloid cells and possibly their direct interaction.
We hypothesized that arming the CAR T cells with a cell-surface ligand capable of activating myeloid cells would determine whether such a direct cellular contact can take place. To address this question, we again took advantage of our xenogeneic model to probe the potential for CD40 ligand (CD40L)-CD40 interactions. As CD40L is mainly expressed by T cells, whereas DCs, monocytes and macrophages express the CD40 receptor 18 , and as human CD40L does not functionally interact with the mCD40 receptor 19 , we constitutively expressed mCD40L in human CAR T cells ( Supplementary  Fig. 6a ,b) and infused these in mice. This modification resulted in more severe and sustained weight loss in mice ( Fig. 3a) and markedly increased mortality (Fig. 3b) . The similar overall number of recruited myeloid cells in the CAR and CAR-mCD40L treatment groups ( Supplementary Fig. 6c ) suggested that the increased severity of CRS was due to qualitative and not quantitative changes in the myeloid compartment. Indeed, mice receiving 1928z-mCD40L CAR T cells showed an increased proportion of CRS-associated macrophages (Fig. 3c) . Notably, although cell-surface expression of CD40 was exclusive to macrophages and DCs in peritoneal myeloid cells ( Supplementary Fig. 6e ), only macrophages downregulated CD40 expression ( Fig. 3d and Supplementary Fig. 6d,f) , an expected consequence of its ligation by CD40L [20] [21] [22] . In line with the increased severity of CRS, levels of murine inflammatory cytokines were significantly increased, including IL-6, which is known to be directly induced by CD40L signaling 23 ( Fig. 3e ). These findings establish that CAR T cell-macrophage interactions can take place at tumor sites, and furthermore, that such interactions, albeit not obligatory, have the potential to aggravate CRS severity. Interestingly, expression of endogenous CD40L positively correlates with CAR expression in human CD4 T cells ( Supplementary  Fig. 6e ), which suggests that such interactions potentially take place in the clinical setting. The genetic manipulation of receptor-ligand pairs in our model further serves as a proof of concept that species barriers can be exploited to investigate immunological interactions between adaptive and innate immune responses in xenogeneic tumor models. Altogether, our enumeration and expression profiling of tumor and splenic myeloid cells, compounded by the exacerbation of CRS via engineered CD40-CD40L interaction, designate CRS-associated macrophages as a major mediator of CRS severity.
To further define the contribution of macrophages to CRS, we investigated the role of inducible nitric oxide synthase (iNOS), an enzyme predominantly expressed by macrophages upon their activation 24 . In line with a requirement for myeloid cell proximity to CAR T cells, only peritoneal, but not splenic or bone marrow, myeloid populations significantly increased iNOS production in CRS (Fig. 3f) . Macrophages showed the highest induction (Fig. 3f) and were numerically the most abundant iNOS-expressing population ( Supplementary Fig. 7a ). Aberrant NO production is known to cause vasodilation and hypotension 25, 26 , which are common features of clinical CRS that require vasopressor administration 9 . We treated mice with one of two iNOS inhibitors: L-NIL 27 or 1400W 28 . Both alleviated clinical toxicity ( Fig. 3g and Supplementary  Fig. 7b ), including mortality under conditions of severe CRS (Fig. 3h) . These findings further support the direct role of macrophage-derived products in CRS and may provide a new means to mitigate CRS severity.
The direct involvement of iNOS in CRS pathophysiology prompted us to further examine the role of IL-6 and IL-1, both of which are inducers of iNOS production 29, 30 . Our RNA-seq data in myeloid cell types harvested at the onset of CRS showed that the type 1 IL-1 receptor (IL1R1), which is required for functional IL-1 signaling, was exclusively upregulated in tumor-associated myeloid cells, but not splenic cells (Fig. 4a,b) . Conversely, splenic myeloid cells upregulated only the type 2 IL-1 receptor (IL1R2), which does not functionally signal and serves as a decoy receptor to blunt proinflammatory IL-1 signaling. We also observed upregulation of IL-1 receptor antagonist (IL1RN/IL-1Ra) in splenic myeloid cells (Fig. 4b) , which suggested an adaptive response to inhibit IL-1 signaling outside of the tumor bed 31 . We hypothesized that endogenously mounted IL-1 suppression was insufficient to inhibit the proinflammatory effects of IL-1 but that a pharmacological intervention could mitigate CRS symptoms. Indeed, IL-1 blockade by anakinra, an IL-1 receptor antagonist, abrogated CRS-related mortality (Fig. 4c) . In order to obtain more insight in the protective mechanism underlying IL-1 blocking and to assess how it compares to IL-6 blockade, we assessed the impact of anakinra on expression levels of iNOS in macrophages. Both blockades resulted in similarly reduced iNOS + macrophage fractions ( Fig. 4d and Supplementary  Fig. 7c ), establishing downregulation of iNOS as one unifying mechanism through which IL-6 and IL-1 blockades can abate severe CRS. Combined IL-1 and IL-6 blockade, however, did not further decrease the fraction of iNOS + macrophages (Fig. 4d) , suggesting that the inhibition afforded by these two blockades operates through a common pathway.
To prevent CRS mortality without exogenous intervention, we engineered CAR T cells to constitutively produce IL-1 receptor antagonist (IL1RN/IL-1Ra) ( Fig. 4e and Supplementary Fig. 8a ). First, we demonstrated that this new construct protects against CRS-associated mortality ( Fig. 4f and Supplementary Fig. 8b ). Importantly, CAR T cell-derived serum cytokine levels were unaffected (Fig. 4g) , consistent with the blockade of endogenous CRS pathways independent of CAR T cell activation. Next, we assessed whether antitumor activity might be affected by evaluating 1928z-mIL1Ra T cells in the CAR 'stress test' at limiting CAR T cell doses in NSG mice 32 . At two different dose levels, 1928z-mIL1Ra Letters NATuRe MeDICINe matched the therapeutic efficacy of control 1928z-LNGFR CAR T cells (Fig. 4h and Supplementary Fig. 8c,d ). Therefore, we not only identified a new actionable target for CRS, but we also designed a CAR construct that autonomously prevents CRS-associated mortality in mice without compromising antitumor efficacy.
We demonstrate here that recipient myeloid cells play a critical role in the pathogenesis of CRS. We establish that tumor-activated CAR T cells recruit and activate myeloid cells, and that colocalized myeloid cells are the main source of IL-6. Macrophages contribute to CRS pathophysiology through their production of . Analysis of peritoneal macrophages for surface expression of CD40 in the presence of the 1928z-mCD40L CAR was performed once. A two-tailed unpaired two-sample t-test was used for statistical analysis. e, Serum levels of mouse cytokines at 18 h following CAR T cell transfer. (Tumor only, n = 8 mice; 1928z-LNGFR, n = 7 mice; 1928z-mCD40L, n = 7 mice). Serum cytokine measurements when using the 1928z-mCD40L CAR were performed once. A two-tailed unpaired two-sample t-test was used for statistical analysis. f, Percentage of myeloid populations from peritoneum, spleen and bone marrow expressing iNOS protein in Tumor only mice and Tumor + CAR mice (for peritoneum, n = 14 mice per group; for spleen and bone marrow, n = 10 mice per group). Peritoneum results are shown from three pooled independent experiments. Spleen and bone marrow results are shown from two pooled independent experiments. A two-tailed unpaired two-sample t-test was used for statistical analysis. g, Weight change of tumor-bearing mice after 1928z CAR T cell transfer. Weight per mouse is normalized to starting weight pre-CAR transfer. Mice were treated with L-NIL or vehicle (PBS) (Tumor only, n = 7 mice; CAR + L-NIL, n = 7 mice; CAR + Vehicle, n = 8 mice). Weight measurement under conditions of CRS was performed once with L-NIL and once with 1400 W (Supplementary Fig. 7b) . A two-way ANOVA was used for statistical analysis. h, Percentage of survival of tumor-bearing mice after 1928z CAR T cell transfer receiving 1400 W or Vehicle (PBS) (Vehicle, n = 20 mice; 1400 W, n = 19 mice). Results were pooled from three independent experiments. A log-rank Mantel-Cox test was used for statistical analysis. All data are shown as mean ± s.e.m. Numbers on the graphs are P values. Green bars, significant downregulation; red bars, significant upregulation; gray bars, no significant change. Gene expression levels were determined from cells obtained from n = 9 Tumor only mice and n = 9 Tumor + CAR mice. Cells from three mice of the same group were randomly pooled to create one biological replicate group to the end of obtaining three biological replicate groups of Tumor only mice and three biological replicate groups of Tumor + CAR mice. A binomial test was used for statistical analysis, and P values were adjusted for FDR. c, Percentage of survival of tumor-bearing mice after 1928z CAR T cell transfer receiving anakinra or vehicle (PBS) (Anakinra, n = 11 mice; Vehicle, n = 10 mice). Results were pooled from two independent experiments. A log-rank Mantel-Cox test was used for statistical analysis. d, Percentage of peritoneal macrophages expressing iNOS at 18 h following CAR T cell transfer. Mice were treated with isotype, mIL-6-blocking antibody, anakinra or mIL-6-blocking antibody + anakinra (Tumor only, n = 4 mice; Isotype, n = 3 mice; Anti-mIL-6, n = 3 mice; Anakinra, n = 3 mice; AntimIL-6 + Anakinra, n = 4 mice). Measurement of the percentage of iNOS + macrophages with isotype or anti-mIL-6 blockade was performed in two independent experiments. Measurement of the percentage of iNOS + macrophages with isotype, anakinra or anakinra + anti-mIL-6-blocking antibody was performed once. A one-way ANOVA was used for statistical analysis. 
Letters
NATuRe MeDICINe IL-6 and iNOS. The aggravation of CRS by CAR T cells expressing mCD40L demonstrates that CAR T cells and macrophages can functionally interact within the tumor microenvironment. Whether CAR T cell-macrophage contact is required for CRS remains to be determined, as CRS could develop in our model in the absence of a functional CD40-CD40L axis. CAR T cells may activate myeloid cells through a variety of other pathways including cytokines, other cell contact-dependent pathways and Toll-like receptor stimulation. Our findings on the importance of CAR T cell-macrophage proximity suggest that the incidence and severity of CRS in CAR therapies will at least in part depend on the extent of myeloid infiltration in the targeted tumor, which may be variable among hematological and solid tumors 33 . Selectively modulating macrophage activity with CD40L, iNOS inhibitors or anakinra revealed the central role played by macrophages and provides insights for new therapeutic interventions. We identified IL-1 as a new actionable target suitable to treat severe CRS and diminish its severity. Although circulating IL-1 levels were below detection, as observed in CD19 CAR T cell recipients undergoing CRS 11 , it is noteworthy that other IL-1-driven inflammatory conditions associated with low or undetectable levels of circulating IL-1 have been found to resolve with the administration of anakinra 34 . Our findings that both induction of IL-1 signaling and of iNOS expression are critical determinants of severe CRS potentially explain why SCID-beige mice develop more severe CRS. SCID-beige mice and NSG mice differ in their genetic background (C.B17-SCID, BALB/c and NOD/LtSz-SCID, NOD/LT, respectively), and the impaired IL-1 response to IFN-γ priming and lipopolysaccharide (LPS) stimulation is found in the NSG background 35 . It is plausible that additional developmental and maturation defects of monocytes and macrophages in NOD mice 36 contribute to reduced macrophage reactivity and diminished CRS in NSG mice. Moreover, NSG mice lack the common γ c chain receptor, which is essential for signaling through IL-2, IL-15 and other cytokines. Peritoneal macrophages lacking γ c are defective in NO production primed by IL-15 signaling 37 , a cytokine that is detected in our mouse model. Our findings informed the design of an IL-1Ra-secreting CAR construct that can demonstrably prevent CRS-related mortality while maintaining intact antitumor efficacy. The benefits of an IL-1 blockade through IL-1Ra are especially intriguing given the latter's ability to cross the blood-brain barrier 38 , unlike tocilizumab 9 . As human microglia activated by IL-1 may produce iNOS and proinflammatory cytokines 39, 40 , blocking IL-1 could potentially not only protect from severe CRS, but also could reduce the severity of CAR T cell-related neurotoxicity.
In addition to the toxicity in itself, CRS carries a high cost because of the stringent patient monitoring and supportive therapy it may require. CRS toxicity and its management costs presently hamper broad use of CAR therapy. This study demonstrates that CAR T cells may be engineered to mitigate these burdens without requiring exogenous intervention.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0041-7. 
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Methods
Cell culture. Burkitt Lymphoma Raji cells and NALM-6 pre-B-ALL cells were obtained from ATCC. Raji GFP-firefly luciferase (FLuc) and NALM-6-GFPFLuc cells were cultured in RPMI (Invitrogen) supplemented with 10% FBS (HyClone), 10 mM HEPES (Invitrogen), l-glutamine 2 mM (Invitrogen), NEAA 1 × (Invitrogen), 0.55 mM β -mercaptoethanol, 1 mM sodium pyruvate (Invitrogen), penicillin-streptomycin 50 U/ml (Invitrogen). Raji and NALM-6 cells were routinely tested for mycoplasma and found to be negative.
Source and handling of T cells. Buffy coats from anonymous healthy donors were purchased from the New York Blood Center (IRB-exempted) and were handled following all required ethical and safety procedures. The researchers were blind to any covariate characteristics.
Isolation and culture of T cells. Primary human T cells were purified from buffy coats of healthy donors by negative magnetic selection (Pan T Cell Isolation Kit, Miltenyi). Purified T cells were cultured in XVIVO 15 (Lonza), supplemented with 5% human serum type AB (Gemini), 10 mM HEPES, 2 mM GlutaMax (Invitrogen), 1 × MEM vitamin solution (Invitrogen), 1 mM sodium pyruvate (Invitrogen), penicillin-streptomycin 50 U/ml (Invitrogen) and 60 U/ml recombinant IL-2. Retroviral vector constructs and retroviral production. The 1928z-LNGFR construct has been previously described 42 . 1928z-mCD40L and 1928z-mIL1RN were prepared using standard molecular biology techniques. To obtain the 1928z-mCD40L construct, the cDNA for mCD40L was inserted in the place of LNGFR. To obtain the 1928z-mIL-1Ra construct, the cDNA for mIL-1Ra was inserted in the place of LNGFR. Plasmids encoding the SFG γ -retroviral (RV) vector 43 were prepared as previously described 42 . gpg29 (H29) cells were transfected to produce VSV-G pseudotyped retroviral supernatants. These supernatants were used to transduce stable retroviral-producing 293 T cell lines as previously described 44 . Retroviral supernatants carrying the various CAR genetic constructs harvested from 293 T cell lines were used to transduce human T cells. T cells were activated with CD3/CD28 T cell Activator Dynabeads (Invitrogen) immediately after purification at a 1:1 bead-to-cell ratio. After 48 h of bead activation, T cells were transduced with retroviral supernatants by centrifugation on Retronectin (Takara)-coated plates in order to obtain 1928z-LNGFR, 1928z-mCD40L or 1928z-mIL-1Ra CAR T cells. Transduction efficiency was verified 3 d later by flow cytometry. CAR T cells were injected in mice 7 d after the first T cell activation. Serum collection. Blood was collected from mice by tail-clip or by retro-orbital bleeding. After collection blood was left to clot for 30 min at room temperature. Following clotting blood was centrifuged at 6,000 g for 10 min at 4 °C. Serum was aliquoted in tubes in order to prevent multiple freeze-thaw cycles and was immediately stored at -80 °C until analysis.
Cytokine measurements. Serum and plasma cytokines were measured using cytometric bead arrays (BD) or ELISA kits for mouse IL-1Ra (Thermo-Fisher), mouse SAA3 (Millipore) and mIL-15-IL-15R complex (Thermo-Fisher), per the manufacturer's instructions.
Animal pathology. Mice were transferred to the pathology core facility of Memorial Sloan Kettering, where they were euthanized by cardiac puncture. Tissues obtained were fixed in 10% buffered formalin and were further processed for H&E staining and immunohistochemistry.
RNA extraction and transcriptome sequencing. Cells were sorted directly into 750 µ l of TRIzol LS (Invitrogen). The volume was adjusted to 1 ml with PBS, and extraction was performed according to instructions provided by the manufacturer. After ribogreen quantification and quality control with an Agilent BioAnalyzer, total RNA underwent amplification using the SMART-seq V4 (Clonetech) Ultra Low Input RNA kit for sequencing. For 2-10 ng of total RNA, 12 cycles of amplification were performed. For a lesser amount (0.13-2 ng), 13 cycles of amplification were performed. Subsequently, 10 ng of amplified cDNA was used to prepare Illumina HiSeq Libraries with the Kapa DNA library preparation chemistry (Kapa Biosystems) using eight cycles of PCR. Samples were barcoded and run on HiSeq 2500 1 T, in a 50bp-50 bp paired-end run, using the TruSeq SBS Kit v3 (Illumina). An average of 38.5 million paired reads were generated per sample, and the percent of mRNA bases was over 77% on average.
RNA-seq analysis. The output FASTQ data files were mapped (two-pass method) to the target genome (MM10 assembly) using the STAR RNA aligner, resolving reads across splice junctions (ENSEMBL assembly). The first mapping pass uses a list of known annotated junctions from ENSEMBL. New junctions found in the first pass are then added to the known junctions, after which a second mapping pass is performed using the RemoveNoncanoncial flag. After mapping, the output SAM files were postprocessed using the Picard Tools utility AddOrReplaceReadGroups to add read groups. The files were then sorted and coverted to BAM format. The expression count matrix for the mapped reads was then computed using HTSeq. Statistical analysis. Statistical analyses were performed using GraphPad Prism V7 for Mac. Statistical tests included the two-tailed unpaired two-sample t-test; the one-way ANOVA; the two-way ANOVA; the log-rank Mantel-Cox test and the binomial test with FDR-adjusted P values. The statistical test used for each figure is described in the corresponding figure legend.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary. In order to elicit CRS, 30 million CAR T cells/mouse were needed, which was a constraining factor. There was an effort to achieve a minimum sample size of n=7 mice per treatment group which proved to be sufficient to reproducibly observe statistically significant differences.
Data exclusions
Describe any data exclusions. Tumour burden was evaluated by in vivo bioluminescent imaging two days prior to CAR T cell transfer. Outlier mice with extreme burdens (either too high or too low compared to most) were excluded from the experiment before CAR T cell infusion. No mice were excluded afterwards at any point.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful. Intensity of CRS could vary between T cell donors.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Tumour burden was evaluated by in vivo bioluminescent imaging two days prior to CAR T cell transfer. Outlier mice with extreme burdens (either too high or too low compared to most) were excluded from the experiment before CAR T cell infusion. No mice were excluded afterwards at any point. Following tumor burden analysis mice were randomly assigned into treatment groups. Buffy coats were obtained from anonymous donors.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
When assessing mouse condition a blinded investigator observed mice in addition to the main investigator, who was not blind to group allocation. Data collection from mice (e.g. weight, serum samples) was performed in blinded fashion. Analysis of data was not performed in blinded fashion.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
